The Drugs.com Monthly Update Podcast

Narrator: 00:01

Welcome to the October 2025 edition of Drugs.com monthly update, where we bring you the latest pharmaceutical news to keep you informed and ahead in the field. This episode uses AI tools to help with formatting, organization, and narration. All content has been reviewed by a senior editorial pharmacist.

Narrator: 00:23

In this episode, we'll delve into several remarkable FDA approvals, such as Rybelsus for cardiovascular risk reduction in diabetes, Gazyva for lupus nephritis, and more innovative therapies changing the landscape of treatment options.

Narrator: 00:40

First, let's discuss Novo Nordisk's Rybelsus, spelled R Y B E L S U S, the first oral GLP-1 receptor agonist now approved for reducing cardiovascular risks in adults with type 2 diabetes, addressing both primary and secondary prevention needs.

Narrator: 01:00

This development is significant because cardiovascular issues are a leading cause of complications in diabetes. The SOUL Phase 3b trial demonstrated Rybelsus's ability to statistically reduce the risk of major adverse cardiovascular events (or MACE) events by 14% over four years compared to placebo, making it an important consideration for managing long term cardiovascular health in this population. However, it's vital to note potential side effects, including gastrointestinal disturbances and acute pancreatitis. Turning to dermatology, the FDA has approved Zoryve cream, spelled Z O R Y V E, for treating mild to moderate atopic dermatitis or eczema in children aged two to five. As a topical phosphodiesterase 4 inhibitor, Zoryve offers a steroid free option that reduces inflammation by modulating the immune response.

Narrator: 01:59

In the INTEGUMENT-PED Phase 3 trial, around 40% of children saw a 75% improvement in 4 weeks, showcasing its efficacy in alleviating this often debilitating condition, with early results noted just after one week of use.

Narrator: 02:17

In autoimmune disease news, Gazyva, spelled G A Z Y V A, has been approved for active lupus nephritis, a serious kidney complication of systemic lupus erythematosus. By targeting B cells to reduce kidney inflammation, Gazyva was shown to provide significant improvements during the Phase 3 REGENCY study with a notable increase in complete renal responses. This new use could potentially transform management for patients battling this severe complication.

Narrator: 02:51

For those dealing with menopause, Bayer's hormone free Lynkuet, spelled L Y N K U E T, has gained approval to ease moderate to severe vasomotor symptoms, like hot flashes, by antagonizing neurokinin receptors in the brain.

Narrator: 03:07

Clinical trials indicate its efficacy in reducing both the number and severity of hot flashes, offering a well tolerated alternative to hormone replacement therapy.

Narrator: 03:17

Moving to cardiovascular disease management. Lasix ONYU, spelled L A S I X O N Y U, provides a novel at home method for managing edema and chronic heart failure with its wearable infusion system. This convenient form of administration ensures patients can self manage fluid overload, enhancing quality of life without frequent hospital visits.

Narrator: 03:44

Lastly, we've seen a new approval for Jascayd, spelled J A S C A Y D, in idiopathic pulmonary fibrosis.

Narrator: 03:54

By inhibiting PDE4B, Jascayd acts to slow lung function decline. The FIBRONEER-IBF trial illustrated its effectiveness, showing a smaller decline in forced vital capacity, (or FVC), a critical measure of lung capacity, proving it to be a valuable tool in managing this chronic lung disease. Thank you for tuning in to the Drugs.com Monthly Update Podcast, where staying informed means staying ahead in your field. We look forward to bringing you more updates next month. Until next time, know more, be sure.